Abstracts Archive - Page 1517 of 2425 - ACR Meeting Abstracts

Abstract Number: 1493 • 2016 ACR/ARHP Annual Meeting
Screening Patterns for Hyperlipidemia Among Patients with Rheumatoid Arthritis Based on Patterns of Care from By Primary Care Physicians, Rheumatologists or Both
Iris Navarro-Millán¹, Shuo Yang², Lang Chen², Huifeng Yun³, Christie M. Bartels⁴, Aprajita Jagpal¹, Andrea Cherrington⁵, Liana Fraenkel⁶, Monika M. Safford⁷ and Jeffrey Curtis⁸, ¹Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Yale University School of Medicine, New Haven, CT, ⁷Weill Cornell Medical College, New York, NY, ⁸Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Coronary heart disease (CHD) is increased among patients with rheumatoid arthritis (RA). Limited data suggest that there is a screening gap for hyperlipidemia, a…
Abstract Number: 1494 • 2016 ACR/ARHP Annual Meeting
Myocardial Structure, Function, and Fibrosis in Patients with Rheumatoid Arthritis and Matched Control Subjects
Michelle J. Ormseth¹, William Bradham², Comfort Elumogo³, Srikanth Palanisamy⁴, Chia Liu⁵, Mark Lawson², Jonathan Soslow², Nadine Kawel⁶, David A. Bluemke⁷ and C Michael Stein², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³National Institutes of Health, Bethesada, MD, ⁴Cornell University, Ithaca, NY, ⁵National Institutes of Health, Bethsada, MD, ⁶National Institutes of Health, Bethsada, TN, ⁷National Institutes of Health, Bethesda, MD
Background/Purpose: The prevalence of heart failure is increased 2-fold in RA; this is not explained by ischemic heart disease or other risk factors for heart…
Abstract Number: 1495 • 2016 ACR/ARHP Annual Meeting
Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Maria Carmen Garcia-Gomez¹, Maria Auxiliadora Martin², Santos Castañeda³, Fernando Sánchez-Alonso⁴, Miren Uriarte Ecenarro⁵, Carlos González-Juanatey⁶, Romera-Baures Monserrat⁷, Santos-Rey Jose⁸, Jose A Pinto-Tasende⁹, Estefania QuesadaMasachs¹⁰, Jesús Tornero¹¹, Olga Martínez González¹², Tatiana Cobo-Ibáñez¹³, Eugenio Chamizo Carmona¹⁴, Sara Manrique-Arija¹⁵, Dolores Fábregas-Canales¹⁶, Federico Díaz-González¹⁷, Javier Llorca¹⁸, Miguel Angel González-Gay¹⁹ and CARMA Collaborative Group, ¹Rheumatology, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁴Research Unit of Spanish Society of Rheumatology, Madrid, Spain, ⁵Donostia University Hospital, San Sebastian, Spain, ⁶Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain, ⁸Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ⁹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ¹⁰Rheumatology, Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁵Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Barbastro (Huesca), Spain, ¹⁷Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ¹⁸Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have…
Abstract Number: 1496 • 2016 ACR/ARHP Annual Meeting
Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease
Alex Zamora-Legoff¹, Megan Krause², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) carries a risk for serious infection due to lung disease, immunosuppressive therapy, and RA disease itself.…
Abstract Number: 1497 • 2016 ACR/ARHP Annual Meeting
Progressive Decline of Lung Function in Rheumatoid Arthritis Associated Interstitial Lung Disease
Alex Zamora-Legoff¹, Megan Krause², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Interstitial lung disease (ILD) is associated with substantial morbidity in rheumatoid arthritis (RA), but virtually nothing is known about the long-term of progression of…
Abstract Number: 1498 • 2016 ACR/ARHP Annual Meeting
Patterns of Interstitial Lung Disease and Associated Mortality in Rheumatoid Arthritis
Alex Zamora-Legoff¹, Cynthia S. Crowson², Megan Krause³, Jay H. Ryu⁴ and Eric L. Matteson³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: To characterize a cohort of patients with rheumatoid arthritis (RA) who have interstitial lung disease (ILD) and to assess the utility of the GAP…
Abstract Number: 1499 • 2016 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease with Rheumatoid Arthritis
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: Serum anti-cyclic citrullinated peptide antibodies (anti-CCP2) positivity was associated with presence of interstitial lung disease and airway disease in rheumatoid arthritis (RA). This study…
Abstract Number: 1500 • 2016 ACR/ARHP Annual Meeting
Concomitant Development of Interstitial Pneumonia Associated with Dermatomyositis and Rheumatoid Arthritis
Takeshi Shoda^1,2, Tohru Takeuchi³, Kentaro Isoda⁴, Takao Kiboshi⁴ and Shigeki Makino³, ¹Division of Clinical Immunology and Rheumatology, Osaka medical college, Osaka, Japan, ²Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan, ³Osaka medical college, Osaka, Japan, ⁴Yodogawa Christian Hospital, Osaka, Japan
Background/Purpose: A few cases of the concomitant development of interstitial pneumonia associated with dermatomyositis (DM-IP) and rheumatoid arthritis (RA) have been reported mainly in Asia,…
Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting
The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Katherine Larson¹, Faizah Siddique² and Samya Mohammad¹, ¹Virginia Commonwealth University, Richmond, VA, ²Department of Veterans Affairs, Richmond, VA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…
Abstract Number: 1502 • 2016 ACR/ARHP Annual Meeting
Vaccination Program to Prevent Hospital Admissions Due to Serious Respiratory Infections in Rheumatoid Arthritis Patients. Prosprective Study of 294 Patients
Lucia C. Domínguez-Casas¹, Paz Rodríguez-Cundín², Vanesa Calvo-Río¹, Ricardo Blanco¹, Nuria Vegas-Revenga³, Carlos Fernández Díaz¹, Virginia Portilla³, FM Antolin², MH Rebollo-Rodrigo², Alfonso Corrales¹, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of infections, especially serious respiratory infections. Immunization is a recommended to reduce these complications.…
Abstract Number: 1503 • 2016 ACR/ARHP Annual Meeting
Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US
Huifeng Yun¹, Shuo Yang², Sofia Pedro³, Jeffrey Curtis⁴ and Kaleb Michaud⁵, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³National Data Bank for Rheumatic Diseases, Wichita, KS, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rates of adult vaccination are low in patients with autoimmune disease despite broad recommendations for many years. In the U.S., pneumococcal vaccination is recommended…
Abstract Number: 1504 • 2016 ACR/ARHP Annual Meeting
Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Karen Ferez-Blando¹, Hilda Fragoso-Loyo², Alfredo Ponce de León³, Sergio Ponce de Leon-Rosales⁴ and Yemil Atisha-Fregoso¹, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Infectology and Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Direccion de Enseñanza, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that requires chronic immunosuppressive treatment. Urinary tract infections (UTI) are common among patients with RA. It…
Abstract Number: 1505 • 2016 ACR/ARHP Annual Meeting
Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013
Sadao Jinno¹, Na Lu^2,3, S. Reza Jafarzadeh⁴ and Maureen Dubreuil^3,5, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁴Medicine, Washington University School of Medicine, St Louis, MO, ⁵Rheumatology, Boston VA HealthCare System, Boston, MA
Background/Purpose: With the increasing uptake of RA treatments that confer infection risk, an increase in the rates of infection hospitalizations among RA patients is expected,…
Abstract Number: 1506 • 2016 ACR/ARHP Annual Meeting
One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients
Laure Gossec¹, Martin Soubrier², Frantz Foissac³, Anna Molto⁴, Thomas Bardin⁵, Francis Berenbaum⁶, Alain Cantagrel⁷, Marie Hélène Cerato⁸, Gerard H. Chales⁹, Isabelle Chary-Valckenaere¹⁰, Bernard Combe¹¹, Emmanuelle Dernis Labous¹², Liana Euller-Ziegler¹³, Rene-Marc Flipo¹⁴, Philippe Gaudin¹⁵, Melanie Gilson¹⁶, Sandrine Guis¹⁷, Xavier Mariette¹⁸, Gaël Mouterde¹⁹, Sophie Pouplin²⁰, Pascal Richette²¹, Alain Saraux²², Thierry Schaeverbeke²³, Jean Sibilia²⁴, Françoise Fayet²⁵ and Maxime Dougados²⁶, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³COMEDRA working group, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Hôpital Lariboisière, Paris, France, ⁶Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁷Purpan Hospital, Toulouse, France, ⁸University Hospital, Toulouse, France, ⁹CHU RENNES, Rennes, France, ¹⁰University Hospital, Nancy, France, ¹¹Lapeyronie Hospital, Montpellier, France, ¹²Le Mans Hospital, Le Mans, France, ¹³Rheumatology, Nice, France, ¹⁴Rheumatology, University Hospital, Lille, France, ¹⁵Rheumatology, Grenoble University Hospital, France, Grenoble, France, ¹⁶Hopital Sud, Grenoble, France, ¹⁷Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, ¹⁸Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ¹⁹Rheumatology Department, Hopital Lapeyronie, Montpellier, France, ²⁰Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²¹Rhumatologie, Hôpital Lariboisière, Paris, France, ²²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ²³Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁵Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ²⁶Cochin Hospital and Paris 05 University, Paris, France
Background/Purpose: Influenza and pneumococcal vaccinations are recommended in all patients with RA. However, it is well known that a gap exists between recommendations and their…
Abstract Number: 1507 • 2016 ACR/ARHP Annual Meeting
Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: According to the report by WHO, Japan is still in moderately-prevailing countries of TB. The annual incidence of TB in Japan is approximately 15/100,000,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].